Results 11 to 20 of about 1,026 (172)

Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48 [PDF]

Liver International
ABSTRACT Background and Aims The safety and tolerability of bulevirtide (BLV), a novel entry inhibitor of hepatitis delta virus, were evaluated in an integrated analysis of clinical trial results from patients with chronic hepatitis delta (CHD).
Maurizia R Brunetto, Tarik Asselah, Pietro Lampertico   +2 more
exaly   +4 more sources

An Exploratory Cost-Utility Analysis of Screening and Treating Immigrants in Canada for Hepatitis D. [PDF]

J Viral Hepat
ABSTRACT Hepatitis D is common among immigrants in Canada, who account for approximately 23% of the population and tend to originate from high‐endemic countries. Mortality rates are notably high among those with chronic infections, and immigrants are less likely to engage in screening and treatment services.
Zhao J, Lewis D, Gamble JM, Butt ZA, Wong WWL.   +4 more
europepmc   +3 more sources

Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide [PDF]

JHEP Reports
Background & Aims: Bulevirtide is a first-in-class entry inhibitor antiviral treatment for chronic hepatitis D. The viral kinetics during bulevirtide therapy and the effect of combining bulevirtide with pegylated-interferon (Peg-IFN) are unknown ...
Selma El Messaoudi, Ségolène Brichler, Claire Fougerou-Leurent, Emmanuel Gordien, Athenaïs Gerber, Amal Kortebi, Garance Lagadic, Miroslava Subic-Levrero, Sophie Metivier, Stanislas Pol, Anne Minello, Vlad Ratziu, Vincent Leroy, Philippe Mathurin, Laurent Alric, Fatoumata Coulibaly, Jean-Michel Pawlotsky, Fabien Zoulim, Victor de Lédinghen, Jérémie Guedj   +19 more
doaj   +2 more sources

Bulevirtide in Chronic Hepatitis D Patients Awaiting Liver Transplantation Results From a French Multicentric Retrospective Study [PDF]

Liver International
International audienceBackground and aims: The impact of bulevirtide in patients awaiting liver transplantation (LT) for decompensated liver disease and/or hepatocellular carcinoma (HCC) is unclear.
Georges-Philippe Pageaux, Magdalena Meszaros, Jérôme Dumortier   +2 more
exaly   +3 more sources

Inhibition of hepatic bile salt uptake by Bulevirtide reduces atherosclerosis in Oatp1a1−/− Ldlr−/− mice

Journal of Lipid Research
Bile salts can strongly influence energy metabolism through systemic signaling, which can be enhanced by inhibiting the hepatic bile salt transporter Na+ taurocholate cotransporting polypeptide (NTCP), thereby delaying hepatic reuptake of bile salts to ...
Begoña Porteiro, Reinout L.P. Roscam Abbing, Wietse In het Panhuis, Dirk R. de Waart, Suzanne Duijst, Isabelle Bolt, Esther W. Vogels, Johannes H.M. Levels, Laura A. Bosmans, Winnie G. Vos, Ronald P.J. Oude Elferink, Esther Lutgens, Stan F.J. van de Graaf   +12 more
doaj   +2 more sources

Efficacy and safety of bulevirtide in patients with chronic hepatitis D and compensated cirrhosis

Терапевтический архив, 2021
Aim. To study the efficacy and safety of bulevirtide, the HBV and HDV entry inhibitor. Materials and methods. Analysis of the results of using bulevirtide in randomized controlled open-label comparative studies MYR202 and MYR203 in 56 patients with ...
Pavel O. Bogomolov, Vladimir T. Ivashkin, Alexey O. Bueverov, Igor V. Maev, Olga I. Sagalova, Snezhana S. Sleptsova, Nikolay D. Yushuk, Denis A. Gusev, Konstantin V. Zhdanov, Vladimir P. Chulanov   +9 more
doaj   +2 more sources

Efficacy and safety of bulevirtide in patients with chronic hepatitis D treated under early access in Switzerland: a retrospective analysis

Swiss Medical Weekly
  BACKGROUND AND AIMS: Bulevirtide 2 mg/day was approved in Switzerland in February 2025 for the treatment of chronic hepatitis D virus (HDV) infection.
Mirjam Kolev, Salomé Wolf, Elizabeth Petràš, Véronique Erard, Beat Helbling, Beat Müllhaupt, David Semela, Felix Stickel, Nasser Semmo   +8 more
doaj   +2 more sources

Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression

JHEP Reports, 2023
Background & Aims: Bulevirtide (BLV) is a novel antiviral drug licensed for the treatment of chronic hepatitis D. Data on the safety and efficacy of stopping BLV therapy upon long-term HDV-RNA suppression are scarce.
Mathias Jachs, Marlene Panzer, Lukas Hartl, Michael Schwarz, Lorenz Balcar, Jeremy V. Camp, Petra Munda, Mattias Mandorfer, Michael Trauner, Stephan W. Aberle, Heinz Zoller, Thomas Reiberger, Peter Ferenci   +12 more
doaj   +2 more sources

Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study

Viruses
Introduction: Hepatitis D virus (HDV) infection remains a significant global health challenge due to its severity and high risk of progression to cirrhosis and hepatocellular carcinoma (HCC). Bulevirtide, a novel HDV entry inhibitor, has shown promise in
Luca Rinaldi, Mauro Viganò, Alessia Ciancio, Alfredo Caturano, Vincenzo Messina, Grazia Anna Niro, Nicolina Capoluongo, Alessandro Loglio, Letizia Marinaro, Aldo Marrone, Ernesto Claar, Maurizio Russello, Emanuela Ciracì, Umberto Vespasiani Gentilucci, Valeria Pace Palitti, Carlo Acierno, Clelia Cosentino, Andrea Mormone, Rosa Cotugno, Francesca Terracciani, Paolo Gallo, Maria Rita Cannavò, Valerio Rosato, Ferdinando Carlo Sasso, Chiara Petrucciello, Giulio Petronio Petronio, Giovanni Villone, Francesco Benanti, Giuseppe Cariti, Elisabetta Falbo, Marco Distefano, Rodolfo Sacco, Alessandro Perrella, Antonio Izzi   +33 more
doaj   +2 more sources

Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy [PDF]

Drug Design, Development and Therapy, 2023
Vicente Soriano,1 Victor Moreno-Torres,1,2 Ana Treviño,1 Octavio Corral,1 Carmen de Mendoza2 1Health Sciences School & Medical Center, Universidad Internacional La Rioja (UNIR), Madrid, Spain; 2Puerta de Hierro University Hospital & Research Institute ...
Soriano V, Moreno-Torres V, Treviño A, Corral O, de Mendoza C   +4 more
doaj   +2 more sources